Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10195249" target="_blank" >RIV/00216208:11110/13:10195249 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/13:43907590 RIV/00064165:_____/13:10195249

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2013/895102" target="_blank" >http://dx.doi.org/10.1155/2013/895102</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2013/895102" target="_blank" >10.1155/2013/895102</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

Popis výsledku v původním jazyce

Incretin-based therapies represent one of the most promising options in type 2 diabetes treatment owing to their good effectiveness with low risk of hypoglycemia and no weight gain. Other numerous potential beneficial effects of incretin-based therapieshave been suggested based mostly on experimental and small clinical studies including its beta-cell-and vasculo-protective actions. One of the recently emerged interesting features of dipeptidyl peptidase-4 (DPP-4) inhibitors is its possible protective effect on the diabetic kidney disease. Here, we review the renal effects of DPP-4 inhibitors with special focus on its influence on the onset and progression of microalbuminuria, as presence of microalbuminuria represents an important early sign of kidneydamage and is also associated with increased risk of hypoglycemia and cardiovascular complications. Mechanisms underlying possible nephroprotective properties of DPP-4 inhibitors include reduction of oxidative stress and inflammation and

Název v anglickém jazyce

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

Popis výsledku anglicky

Incretin-based therapies represent one of the most promising options in type 2 diabetes treatment owing to their good effectiveness with low risk of hypoglycemia and no weight gain. Other numerous potential beneficial effects of incretin-based therapieshave been suggested based mostly on experimental and small clinical studies including its beta-cell-and vasculo-protective actions. One of the recently emerged interesting features of dipeptidyl peptidase-4 (DPP-4) inhibitors is its possible protective effect on the diabetic kidney disease. Here, we review the renal effects of DPP-4 inhibitors with special focus on its influence on the onset and progression of microalbuminuria, as presence of microalbuminuria represents an important early sign of kidneydamage and is also associated with increased risk of hypoglycemia and cardiovascular complications. Mechanisms underlying possible nephroprotective properties of DPP-4 inhibitors include reduction of oxidative stress and inflammation and

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Endocrinology

ISSN

1687-8337

e-ISSN

—

Svazek periodika

Neuveden

Číslo periodika v rámci svazku

Sep 5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

000324425000001

EID výsledku v databázi Scopus

—